Last reviewed · How we verify
Dorzolamide 2%-timolol 0.5%
At a glance
| Generic name | Dorzolamide 2%-timolol 0.5% |
|---|---|
| Also known as | Cosopt, RVD intervention after run-in on timolol 0.5% bid OU |
| Sponsor | Massachusetts Eye and Ear Infirmary |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients (PHASE4)
- Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. (PHASE4)
- Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno® (PHASE1)
- Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy (NA)
- Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide (PHASE2)
- Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma (PHASE4)
- Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dorzolamide 2%-timolol 0.5% CI brief — competitive landscape report
- Dorzolamide 2%-timolol 0.5% updates RSS · CI watch RSS
- Massachusetts Eye and Ear Infirmary portfolio CI